集群蛋白是阿尔茨海默氏症疾病中潜在的治疗点
Nazhakaiti Palihati1, Yuanhong Tang1, Yajuan Yin2
1Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, Beijing, 100081, China.
Molecular neurobiology
|November 28, 2023
概括
集群蛋白是一种与阿尔茨海默氏症 (AD) 相关的蛋白质,影响其发展和进展. 了解clusterin的作用是早期AD诊断和新的治疗策略的关键.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生化学
- 病理学 病理学 病理学
背景情况:
- 集群蛋白是一种多功能甘油蛋白质,涉及各种生理和病理过程.
- 最近的研究强调了Clusterin在阿尔茨海默病 (AD) 的发展和进展中的重要参与.
研究的目的:
- 阐明Clusterin在阿尔茨海默氏症病原发生中的多方面的作用.
- 探索Clusterin作为一种潜在的AD诊断和监测治疗疗效的生物标志物.
主要方法:
- 对AD脑组织中clusterin表达现实的现有文献的综述.
- 对Clusterin在β-粉样蛋白沉积和清除中的参与进行分析.
- 研究Clusterin对AD相关途径 (如炎症和亡) 的影响.
主要成果:
- 在阿尔茨海默氏症大脑组织中增加的集群蛋白表达与疾病进展相关.
- 集群蛋白积极参与β-粉样斑块的形成和聚合.
- 克劳斯特林通过调节炎症反应,亡和蛋白质清除来影响AD的发病.
结论:
- 集群素是阿尔茨海默病病因和进展的关键因素.
- 对Clusterin机制的进一步研究为AD的新型诊断和治疗干预提供了潜力.
- 集群蛋白显示为AD诊断和治疗监测的有价值的生物标志物.
相关概念视频
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Alzheimer's Disease: Overview
494
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.3K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.3K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
128
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
128
Ligand-gated Ion Channels
12.4K
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
12.4K
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K


